Back to homepage

Tag "PARP inhibitor"

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Authors: Marisa C Liu MD, MPH, Krishnansu S Tewari MD

This review summarizes studies related to anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition of ovarian cancer and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.

More

Advances in the use of PARP inhibitor therapy for breast cancer

Authors: Kelly E McCann MD, PhD, Sara A Hurvitz MD

In the care of oncology patients, poly-ADP-ribose polymerase (PARP) inhibitors are best known as a semitargeted treatment
for BRCA1- and BRCA2-associated ovarian and breast cancers, this article reviews the broader understanding of PARP biology that has spurred interest in expanding their clinical utility.

More